Vident Advisory LLC Raises Stake in Insmed, Inc. $INSM

Key Points

• Vident Advisory LLC significantly increased its stake in Insmed, Inc. by 38.8%, bringing its total holdings to 6,855 shares valued at approximately $523,000.
• Multiple hedge funds adjusted their holdings in Insmed, with Driehaus Capital Management LLC increasing its stake by 93.5% during the same period.
• Analysts have upgraded their price targets for Insmed, with firms like Wells Fargo and Mizuho raising targets to $171.00 and $165.00 respectively, reflecting strong bullish sentiment for the company's future.

Vident Advisory LLC boosted its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 38.8% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 6,855 shares of the biopharmaceutical company's stock after acquiring an additional 1,918 shares during the period. Vident Advisory LLC's holdings in Insmed were worth $523,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. M&T Bank Corp raised its stake in Insmed by 4.7% in the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock valued at $252,000 after acquiring an additional 147 shares during the period. Snowden Capital Advisors LLC raised its stake in Insmed by 2.5% in the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock valued at $456,000 after acquiring an additional 158 shares during the period. Cullen Frost Bankers Inc. raised its stake in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 221 shares during the period. Nisa Investment Advisors LLC raised its stake in Insmed by 6.5% in the 1st quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock valued at $287,000 after acquiring an additional 228 shares during the period. Finally, Parkman Healthcare Partners LLC raised its stake in Insmed by 0.7% in the 4th quarter. Parkman Healthcare Partners LLC now owns 35,668 shares of the biopharmaceutical company's stock valued at $2,463,000 after acquiring an additional 235 shares during the period.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of research reports. The Goldman Sachs Group boosted their price objective on Insmed from $114.00 to $142.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. Citigroup raised Insmed to a "buy" rating in a report on Tuesday, June 10th. Jefferies Financial Group lifted their target price on Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. Guggenheim lifted their target price on Insmed from $125.00 to $172.00 and gave the company a "buy" rating in a report on Monday. Finally, Mizuho lifted their target price on Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. Sixteen analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, Insmed currently has an average rating of "Moderate Buy" and a consensus price target of $139.86.

Insmed Price Performance

Shares of NASDAQ INSM traded up $0.14 during midday trading on Friday, hitting $145.93. 1,926,423 shares of the company's stock were exchanged, compared to its average volume of 2,206,758. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $149.08. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The company has a market cap of $30.85 billion, a price-to-earnings ratio of -25.56 and a beta of 0.97. The business's fifty day moving average price is $119.40 and its two-hundred day moving average price is $91.91.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million for the quarter, compared to analysts' expectations of $104.06 million. During the same period in the previous year, the firm posted ($1.94) EPS. The firm's revenue for the quarter was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 129,805 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $100.39, for a total value of $13,031,123.95. Following the completion of the sale, the chief executive officer owned 233,924 shares of the company's stock, valued at $23,483,630.36. This represents a 35.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Melvin Md Sharoky sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $129.50, for a total value of $1,295,000.00. Following the completion of the sale, the director directly owned 274,516 shares of the company's stock, valued at approximately $35,549,822. This represents a 3.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 378,382 shares of company stock valued at $40,169,038 in the last ninety days. Insiders own 3.00% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.